2seventy bio Inc (TSVT)
4.59
+0.34
(+7.87%)
USD |
NASDAQ |
Apr 29, 16:00
4.52
-0.07
(-1.53%)
Pre-Market: 09:07
2seventy bio Revenue (TTM): 100.39M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 100.39M |
| September 30, 2023 | 145.88M |
| June 30, 2023 | 147.25M |
| March 31, 2023 | 124.69M |
| December 31, 2022 | 91.50M |
| September 30, 2022 | 51.35M |
| Date | Value |
|---|---|
| June 30, 2022 | 57.20M |
| March 31, 2022 | 51.05M |
| December 31, 2021 | 54.52M |
| September 30, 2021 | 48.39M |
| June 30, 2021 | 47.57M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
47.57M
Minimum
Jun 2021
147.25M
Maximum
Jun 2023
83.62M
Average
57.20M
Median
Jun 2022
Revenue (TTM) Benchmarks
| Bristol-Myers Squibb Co | 45.53B |
| Johnson & Johnson | 89.66B |
| Regeneron Pharmaceuticals Inc | 13.12B |
| Macrogenics Inc | 56.91M |
| Akebia Therapeutics Inc | 194.74M |